<SEC-DOCUMENT>0001683168-25-001631.txt : 20250317
<SEC-HEADER>0001683168-25-001631.hdr.sgml : 20250317
<ACCEPTANCE-DATETIME>20250317080036
ACCESSION NUMBER:		0001683168-25-001631
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250316
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Material Modifications to Rights of Security Holders
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250317
DATE AS OF CHANGE:		20250317

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AETHLON MEDICAL INC
		CENTRAL INDEX KEY:			0000882291
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				133632859
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37487
		FILM NUMBER:		25742416

	BUSINESS ADDRESS:	
		STREET 1:		11555 SORRENTO VALLEY ROAD, SUITE 203
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		619-941-0360

	MAIL ADDRESS:	
		STREET 1:		11555 SORRENTO VALLEY ROAD, SUITE 203
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BISHOP EQUITIES INC
		DATE OF NAME CHANGE:	19930602
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>aemd_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:AEMD="http://aethlonmedical.com/20250216">
<head>
     <title>AETHLON MEDICAL, INC. 8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_034_AEMD_aethlonmedical.com_20250216 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20250316_20250316 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DEntityCentralIndexKey_0000882291 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-03-16" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-03-16" id="Fact000004" name="dei:EntityCentralIndexKey">0000882291</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="aemd-20250216.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-03-16">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-16</xbrli:startDate>
        <xbrli:endDate>2025-03-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt"><b>FORM <span id="xdx_90F_edei--DocumentType_c20250316__20250316_zNcVtV98PYk1"><ix:nonNumeric contextRef="AsOf2025-03-16" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d) </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
<b><span id="xdx_90D_edei--DocumentPeriodEndDate_c20250316__20250316_zmgJbAs0J7cf"><ix:nonNumeric contextRef="AsOf2025-03-16" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">March 16, 2025</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_90A_edei--EntityRegistrantName_c20250316__20250316_ziewP9RwesXe" style="font-size: 18pt"><b><ix:nonNumeric contextRef="AsOf2025-03-16" id="Fact000011" name="dei:EntityRegistrantName">Aethlon
Medical, Inc.</ix:nonNumeric></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its
charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: Black 1pt solid; vertical-align: top; width: 39%; font-size: 10pt; text-align: center"><b><span id="xdx_900_edei--EntityIncorporationStateCountryCode_c20250316__20250316_znMNRn8CpLV6"><ix:nonNumeric contextRef="AsOf2025-03-16" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: top; width: 22%; font-size: 10pt; text-align: center"><b><span id="xdx_90C_edei--EntityFileNumber_c20250316__20250316_zQhvT6NM5eY7"><ix:nonNumeric contextRef="AsOf2025-03-16" id="Fact000013" name="dei:EntityFileNumber">001-37487</ix:nonNumeric></span></b></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: top; width: 39%; font-size: 10pt; text-align: center"><b><span id="xdx_901_edei--EntityTaxIdentificationNumber_c20250316__20250316_zuKttVx2KPKg"><ix:nonNumeric contextRef="AsOf2025-03-16" id="Fact000014" name="dei:EntityTaxIdentificationNumber">13-3632859</ix:nonNumeric></span></b></td></tr>
  <tr>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of
    incorporation)</p></td>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Commission File Number)</p></td>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(IRS Employer Identification No.)</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: Black 1pt solid; vertical-align: top; width: 50%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90E_edei--EntityAddressAddressLine1_c20250316__20250316_zlGgk2nRBGQ7"><ix:nonNumeric contextRef="AsOf2025-03-16" id="Fact000015" name="dei:EntityAddressAddressLine1">11555
    Sorrento Valley Road</ix:nonNumeric></span>, <span id="xdx_90D_edei--EntityAddressAddressLine2_c20250316__20250316_z4PoHM9mkWb2"><ix:nonNumeric contextRef="AsOf2025-03-16" id="Fact000016" name="dei:EntityAddressAddressLine2">Suite
    203</ix:nonNumeric></span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_908_edei--EntityAddressCityOrTown_c20250316__20250316_zTJe38SGeIK2"><ix:nonNumeric contextRef="AsOf2025-03-16" id="Fact000017" name="dei:EntityAddressCityOrTown">San Diego</ix:nonNumeric></span>, <span id="xdx_902_edei--EntityAddressStateOrProvince_c20250316__20250316_zKL2EP32vUMe"><ix:nonNumeric contextRef="AsOf2025-03-16" format="ixt-sec:stateprovnameen" id="Fact000018" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span></b></p></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center; width: 50%"><b><span id="xdx_901_edei--EntityAddressPostalZipCode_c20250316__20250316_zaRfkBUlROT7"><ix:nonNumeric contextRef="AsOf2025-03-16" id="Fact000019" name="dei:EntityAddressPostalZipCode">92121</ix:nonNumeric></span></b></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center">(Address of principal executive offices)</td>
    <td style="vertical-align: top; text-align: center">(Zip Code)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number, including
area code: <b>(<span id="xdx_90D_edei--CityAreaCode_c20250316__20250316_zSzSuaBfcXgh"><ix:nonNumeric contextRef="AsOf2025-03-16" id="Fact000020" name="dei:CityAreaCode">619</ix:nonNumeric></span>)</b><b> <span id="xdx_90B_edei--LocalPhoneNumber_c20250316__20250316_zjjV6imPHAfk"><ix:nonNumeric contextRef="AsOf2025-03-16" id="Fact000021" name="dei:LocalPhoneNumber">941-0360</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>N/A </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed since
last report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_edei--WrittenCommunications_c20250316__20250316_zISH2C7Cf4O9"><ix:nonNumeric contextRef="AsOf2025-03-16" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_edei--SolicitingMaterial_c20250316__20250316_zPdk0u9ASDpb"><ix:nonNumeric contextRef="AsOf2025-03-16" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_edei--PreCommencementTenderOffer_c20250316__20250316_zrfNtZYIKWb1"><ix:nonNumeric contextRef="AsOf2025-03-16" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_edei--PreCommencementIssuerTenderOffer_c20250316__20250316_zXxflaea9HZh"><ix:nonNumeric contextRef="AsOf2025-03-16" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="border: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 40%; text-align: center">Title of each class</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; width: 20%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Trading Symbol(s)</p></td>
    <td style="border-bottom: Black 1pt solid; width: 40%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Name of each exchange on which registered</p></td></tr>
  <tr>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_909_edei--Security12bTitle_c20250316__20250316_zPkqXZNOuVw6"><ix:nonNumeric contextRef="AsOf2025-03-16" id="Fact000026" name="dei:Security12bTitle">Common Stock, $0.001 par value per share</ix:nonNumeric></span></b></p></td>
    <td style="border-right: Black 1pt solid; border-left: Black 1pt solid; vertical-align: top; text-align: center"><b><span id="xdx_90F_edei--TradingSymbol_c20250316__20250316_zbzK1WuCvXgc"><ix:nonNumeric contextRef="AsOf2025-03-16" id="Fact000027" name="dei:TradingSymbol">AEMD</ix:nonNumeric></span></b></td>
    <td style="vertical-align: top; text-align: center"><b>The <span id="xdx_906_edei--SecurityExchangeName_c20250316__20250316_zfjcwLa4I4k8"><ix:nonNumeric contextRef="AsOf2025-03-16" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (&#167; 240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Emerging growth company <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_edei--EntityEmergingGrowthCompany_c20250316__20250316_zMkaoENrCF18"><ix:nonNumeric contextRef="AsOf2025-03-16" format="ixt:booleanfalse" id="Fact000029" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&#160;<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Item 1.01 Entry into a Material Definitive
Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Warrant Inducement
Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 16, 2025,&#160;<span style="background-color: white">Aethlon
Medical, Inc. (the &#8220;Company&#8221;)&#160;</span>entered into a inducement offer to exercise existing Class A and Class B Warrants
(the &#8220;Agreement&#8221;) with a certain accredited and institutional holder (the &#8220;Holder&#8221;) of the Company&#8217;s outstanding
Class A and Class B Warrants issued on May 17, 2024 (the &#8220;Existing Warrants&#8221;). Pursuant to the Agreement, the Holder, upon
exercise, will receive a new unregistered Common Stock Purchase Warrant (&#8220;New Warrant&#8221;) pursuant to Section 4(a)(2) of the
Securities Act of 1933, as amended (&#8220;Securities Act&#8221;), to purchase up to a number of shares equal to 200% of the number of
Warrant Shares issued pursuant to the exercise of Existing Warrants pursuant to this Agreement (the &#8220;New Warrant Shares&#8221;),
which New Warrant shall have an exercise price per share equal to $0.3736, subject to adjustment as provided in the New Warrant, will
be exercisable at any time on or after six (6) months from the date of issuance and have a term of exercise of five and one-half (5.5)
years from the date of issuance and (ii) a reduction of the exercise price of the Existing Warrants to $0.3736 per share, representing
the closing price on March 14, 2025, but only with respect to a cash exercise under&#160;the Existing Warrants (as reduced from the current
respective exercise price per share as set forth in the Existing Warrants).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The closing took place on March 17, 2025. Gross
proceeds to the Company from the exercise of the Existing Warrants was approximately $2,316,320 million, prior to deducting closing costs
and placement agent fees as further described below. The Company intends to use the net proceeds from the offering for working capital
and general corporate purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">As a result of the Holder
exercising the Existing Warrants, the Company issued an aggregate of 6,200,000 shares of its common stock. The shares underlying the Existing
Warrants have all been registered on Form S-1 registration statement (Registration Number 333-278188).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company agreed to
file a resale registration statement registering the shares underlying the Replacement Warrants (&#8220;Resale Registration Statement&#8221;)
within ninety (90) days of the date of the Agreement and to use commercially reasonable best efforts to cause the Resale Registration
Statement to be effective on or prior to the 150th calendar day after the date of the Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Subject to the terms
of the Agreement, the Company will be required to pay certain liquidated damages if the shares underlying the New Warrants are not filed
within the ninety (90) period, as more fully described in the Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company further agreed
that until sixty (60) days after the closing date of the warrant exercise, it will not (other than in connection with limited enumerated
exceptions) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of common stock or common
stock equivalents or file any registration statement or any amendment or supplement (other than the registration statement registering
the shares underlying the Replacement Warrants).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In connection with the
transactions contemplated in the Agreement, the Company agreed to pay its placement agent, Maxim Group, LLC (the &#8220;Agent&#8221;)
the following compensation, (i) a cash fee equal to 6.0% of the gross proceeds received by the Company in the transactions contemplated
by the Agreement, and (ii)&#160;<span style="background-color: white">legal fees and out-of-pocket expenses&#160;</span>of $15,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The foregoing descriptions
of the Agreement and the New Warrants do not purport to be complete and are qualified in their entirety by reference to the full text
of the Agreement and the New Warrants copies of which are attached to this Current Report on Form 8-K as Exhibits 10.01, 4.01, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Terms of New Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Stockholder Approval.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">In order to retroactively approve
the Reset of the Exercise Price provision of the New Warrants, the Company shall hold an annual or special meeting of stockholders on
or prior to the date that is one hundred and twenty (120) days following the Issue Date for the purpose of obtaining Stockholder Approval.
If Stockholder Approval is not obtained at the first such meeting held pursuant to this paragraph, the Company shall include the such
proposal in the following two (2) annual meetings of stockholders thereafter. However, should the Company not obtain Stockholder Approval,
the terms of such provision remains.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Duration and Exercise Price.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each New Warrant has&#160;<span style="background-color: white">an
initial exercise price equal to $0.3736 per share, subject to adjustment, will be exercisable six (6) months from the date of issuance,
and will expire five and one half (5.5) years from the date of issuance. The exercise price and number of shares of common stock issuable
upon exercise is subject to appropriate adjustment in the</span>&#160;event of stock dividends, stock splits, reorganizations or similar
events affecting our shares of common stock and the exercise price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Exercisability.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The New Warrants will be exercisable,
at the option of the Holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full for
the number of shares of common stock purchased upon such exercise (except in the case of a cashless exercise, as discussed below). Holder
(together with its affiliates) may not exercise any portion of the New Warrants to the extent that the Holder would own more than 4.99%
(or, at the election of the Holder, 9.99%) of the outstanding shares of common stock immediately after exercise. If Stockholder Approval
is not obtained at the first such meeting held pursuant to this paragraph, the Company shall include the such proposal in the following
two (2) annual meetings of stockholders thereafter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Cashless Exercise.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If at the time Holder exercises its New Warrants,
a registration statement registering the issuance of the shares of common stock underlying the New Warrants under the Securities Act is
not then effective or the prospectus contained therein is not available for the resale of the Warrant Shares, then in lieu of making the
cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the Holder may elect
instead to receive upon such exercise (either in whole or in part) the net number of shares of common stock determined according to a
formula set forth in the New Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Transferability.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to applicable laws, a New Warrant may
be transferred at the option of the Holder upon surrender of the New Warrant to us together with the appropriate instruments of transfer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Exchange Listing.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no trading market available for the New
Warrants on any securities exchange or nationally recognized trading system. We do not intend to list the New Warrants on any securities
exchange or nationally recognized trading system.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Right as a Stockholder.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as otherwise provided in the New Warrants
or by virtue of such Holder&#8217;s ownership of our shares of common stock, the Holders of the New Warrants do not have the rights or
privileges of Holders of our shares of common stock, including any voting rights, until the&#160;<span style="background-color: white">Holder
exercises</span>&#160;their New Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i></i></b></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Fundamental Transaction.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of a fundamental transaction, as
described in the New Warrants and generally including any reorganization, recapitalization or reclassification of our shares of common
stock, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation or merger with
or into another person, the acquisition of more than 50% of our outstanding shares of common stock, or any person or group becoming the
beneficial owner of more than 50% of the voting power represented by our outstanding shares of common stock, the Holders of the New Warrants
will be entitled to receive upon exercise of the New Warrants the kind and amount of securities, cash or other property that the Holders
would have received had they exercised the New Warrants immediately prior to such fundamental transaction. Additionally, as more fully
described in the New Warrants, in the event of certain fundamental transactions, the Holders of the New Warrants will be entitled to receive
consideration in an amount equal to the Black Scholes value of the New Warrants on the date of consummation of the transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 3.02</b> <b>Unregistered Sales of Equity
Securities.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The information set forth
in Item 1.01 of this current report on Form 8-K is incorporated herein by reference in its entirety. Neither <span style="background-color: white">the
issuance of the New Warrants or the shares of common stock issuable upon the exercise of the New Warrants have been registered under the
Securities Act and such securities may not be offered or sold in the United States absent registration or an exemption from registration
under the Securities Act and any applicable state securities laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Item 3.03 Material
Modifications to Rights of Security Holders. </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The disclosure set forth
under Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.03 in its entirely.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Item 9.01 Financial
Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>(d) Exhibits</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="border-bottom: Black 1pt solid; vertical-align: top; width: 72px"><span style="font-size: 10pt"><b>Exhibit Number</b></span></td>
    <td style="vertical-align: top; width: 14px">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom"><span style="font-size: 10pt"><b>Description</b></span></td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">4.1</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="aemd_ex0401.htm">Form of New Warrant</a></span></td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">10.1</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="aemd_ex1001.htm">Form of Inducement Letter</a></span></td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">104</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">Cover Page Interactive Data File (embedded within the inline XBRL Document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Date: March 17, 2025</span></td>
    <td colspan="2"><span style="font-size: 10pt"><b>Aethlon Medical, Inc.</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 52%">&#160;</td>
    <td style="width: 5%"><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; width: 43%"><span style="font-size: 10pt">/s/ James B. Frakes</span></td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Name:</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></td>
    <td style="vertical-align: bottom">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">James B. Frakes</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Chief Executive Officer and Chief Financial Officer</i></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>





<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKgkAQRb/Afxj2OUyX6sHHpCKyEInodckxlnRHZrfST+ovW5VouDAM9565QszEjra6RobrusjgjE1bK4dQYIWM5oY+ke4PCfhd4F1bx8q48fyBKXkGPbMMpVTeGKMvbbFMIFrM5SCIVkkcQ34UweCnZCpdonFa1aBMCTlTyxqd4n76cFYdGWr6seqCbDWZBOIwmuwPyCiWcKKXehM/LGRZKoLZOIHYMT1bn9p0Ds1AwqbGxtfZif4r+AIFFUqK -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>aemd_ex0401.htm
<DESCRIPTION>FORM OF NEW WARRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>Exhibit 4.1</B></P>

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH
THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE
IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;), AND,
ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO
AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE
WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION
WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>AETHLON
MEDICAL, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: left; width: 50%">Warrant Shares: _______</TD>
  <TD STYLE="text-align: right; padding-left: 10pt; text-indent: -0.01pt; width: 50%">Original Issuance Date: March [ ], 2025</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">THIS COMMON STOCK PURCHASE WARRANT
(the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its assigns (the &ldquo;<U>Holder</U>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
September [ ], 2025 (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00 p.m. (New York City time) on September [
], 2030 (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from Aethlon Medical, Inc., a Nevada
corporation (the &ldquo;<U>Company</U>&rdquo;), up to ______ shares (as subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;)
of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in
Section 2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 1</U>.&nbsp;&nbsp;&nbsp;<U>Definitions</U>.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement
(the &ldquo;<U>Purchase Agreement</U>&rdquo;), dated March [-], 2025, among the Company and the purchasers signatory thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 2</U>.&nbsp;&nbsp;&nbsp;&nbsp;<U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Exercise of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any
time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed
PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;).
Within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined
in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the
Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank
unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original
Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of
Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant
to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full,
in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which
the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the
total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable
hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing
the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise
within one (1) Trading Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree
that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of
Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Exercise Price</U>. The exercise price per share of Common Stock under this Warrant shall be <B>$0.3736</B>, subject to adjustment
hereunder (the &ldquo;<U>Exercise Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">c)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Cashless Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus
contained therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may also be exercised, in whole
or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant
Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 2pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 11%"></TD><TD STYLE="width: 4%; text-align: left">(A) =</TD><TD STYLE="text-align: justify; width: 80%">as applicable: (i) the VWAP on the Trading Day immediately preceding
the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a)
hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to
the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities
laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of
the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P.
(&ldquo;<U>Bloomberg</U>&rdquo;) as of the time of the Holder&rsquo;s execution of the applicable Notice of Exercise if such Notice of
Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading Day and is delivered within two (2) hours thereafter (including
until two (2) hours after the close of &ldquo;regular trading hours&rdquo; on a Trading Day) pursuant to Section 2(a) hereof or (iii)
the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of
Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &ldquo;regular trading hours&rdquo; on such
Trading Day;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 2pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 11%"></TD><TD STYLE="width: 4%; text-align: left">(B) =</TD><TD STYLE="text-align: justify; width: 80%">the Exercise Price of this Warrant, as adjusted hereunder; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 2pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 11%"></TD><TD STYLE="width: 4%; text-align: left">(X) =</TD><TD STYLE="text-align: justify; width: 80%">the number of Warrant Shares that would be issuable upon exercise
of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless
exercise.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised.&nbsp;&nbsp;The Company
agrees not to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Bid Price</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading
Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City
time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the
Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed
or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization
or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in
all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by
the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses
of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a
similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock
so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant
to this Section 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"> <FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">d)</FONT> <U>Mechanics of Exercise</U>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">i.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted
by the Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository
Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in
such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of
the Warrant Shares by Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of a certificate,
registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which
the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is
the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery
of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the
delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;). Upon delivery of
the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares
with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment
of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by the Warrant Share Delivery Date. If the
Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery
Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject
to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing
to $20 per Trading Day on the fifth (5th) Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share
Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent
that is a participant in the Fast Automated Securities Transfer Program (FAST program) so long as this Warrant remains outstanding and
exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number
of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of
the Notice of Exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">ii.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request
of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new
Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall
in all other respects be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">iii.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Rescission Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant
to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise by notifying the Company
of such rescission at any time prior to the delivery of the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">iv.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available
to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions
of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required
by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares
of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such
exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s
total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained
by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise
at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in
which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common
Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with
an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the
Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit
a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree
of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock
upon exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">v.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>No Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">vi.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Charges, Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer
tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the
Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder;
<U>provided</U>, <U>however</U>, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder,
this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and
the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.
The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository
Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of
the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">vii.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Closing of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"> <FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">e)</FONT> <U>Holder&rsquo;s Exercise Limitations</U>. The Company shall not affect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp; For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties.&nbsp; Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any reports or schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&nbsp; Upon the written or oral request of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.&nbsp; In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be 4.99% (or 9.99% at the election of the Holder) of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 3</U>.&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or
otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable
in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise
of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way
of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares
of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction
of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before
such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the
number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this
Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record
date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after
the effective date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Reserved</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">c)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time while this Warrant
is outstanding the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other
property pro rata to the record holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder
will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have
acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard
to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date
on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which
the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>,
<U>however</U>, that, to the extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder
exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent
(or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to
such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding
the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">d)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Pro Rata Distributions</U>. Except in the case of a Fundamental Transaction to which Section 3(e) below is applicable or to
which a notice under Section 3(g)(ii) below applies, during such time as this Warrant is outstanding, if the Company shall declare or
make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of
return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options
by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>,
<U>however</U>, that, to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding
the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the
beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution
shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder
exceeding the Beneficial Ownership Limitation). To the extent that this Warrant has not been partially or completely exercised at the
time of such Distribution, such portion of the Distribution shall be held in abeyance for the benefit of the Holder until the Holder has
exercised this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">e)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Fundamental Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in
one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company or any
Subsidiary, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or
substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer
or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell,
tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding
Common Stock or 50% or more of the voting power of the outstanding common stock of the Company, (iv) the Company, directly or indirectly,
in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory
share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or
(v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other
business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with
another Person or group of Persons whereby such other Person or group acquires 50% or more of the outstanding shares of Common Stock or
50% or more of the voting power of the outstanding common stock of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;),
then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have
been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without
regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring
corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable
immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant).
For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate
Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction,
and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value
of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash
or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration
it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor entity in
a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all
of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section
3(e) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable
delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant
a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which
is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the
shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this
Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of
capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the
value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting
the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory
in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and
be substituted for the Company (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant and the
other Transaction Documents referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity), and the Successor Entity
may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant and the other
Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">f)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Calculations</U>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share,
as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given
date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">g)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Notice to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">i.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company
shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">ii.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Notice to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form)
on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with
any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any
sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into
other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding
up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email
address as it shall appear upon the Warrant Register of the Company, at least 10 calendar days prior to the applicable record or effective
date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution,
redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be
entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected
that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other
property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to
deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to
be specified in such notice. To the extent that the Company, in consultation with its legal counsel, determines that any notice provided
in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company
shall comply with (i) its disclosure obligations under Regulation FD and (ii) the applicable instructions to Form 8-K. The Holder shall
remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering
such notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">h)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Voluntary Adjustment By Company</U>. Subject to the rules and regulations of the Trading Market, the Company may at any time
during the term of this Warrant reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by
the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">i)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT><U>Reset of Exercise Price</U>. If, on the date that is 12 calendar days immediately following the initial issuance date of this
Warrant (the issuance date of this Warrant, the &ldquo;<U>Issuance Date</U>&rdquo; and the date that is 12 calendar days following the
Issuance Date, the &ldquo;<U>Reset Date</U>&rdquo;), the Reset Price, as defined below, is less than the Exercise Price at such time,
the Exercise Price shall be decreased to the Reset Price; provided, however, that if at the Reset Date, the Reset Price is greater than
or equal to the Exercise Price, then there shall be no adjustment to the Exercise Price on the Reset Date. &ldquo;Reset Price&rdquo; shall
mean 100% of the trailing five day VWAP immediately preceding the Reset Date, <U>provided</U>, that in no event shall the Reset Price
be less than 20% of the most recent closing price at the time of execution of the warrant inducement (subject to adjustment for reverse
and forward stock splits, recapitalizations and similar transactions following the date of the warrant inducement); provided, however,
this provision in Section 3(i) shall be subject to approval at either (i) the special meeting of the stockholders to be held at the earliest
practicable date after the date hereof, or (ii) the Company&rsquo;s next two (2) annual meetings of stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 4</U>.&nbsp;&nbsp;&nbsp;&nbsp;<U>Transfer
of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Transferability</U>. This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable,
in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written
assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient
to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall
execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so
assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall
surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the
Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for
the purchase of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>New Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office
of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division
or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided
or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of
this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">c)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT><U>Warrant Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose
(the &ldquo;<U>Warrant Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat
the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder,
and for all other purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 5</U>.&nbsp;&nbsp;&nbsp;&nbsp;<U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>No Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights,
dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly
set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant
to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be
required to net cash settle an exercise of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares,
and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant,
shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the
Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant
or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">c)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right
required or granted herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding
Trading Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">d)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Authorized Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number
of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further
covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the
necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action
as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation,
or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares
which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented
by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable
and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any
transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its articles
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior
to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and
legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts
to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary
to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">e)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall
be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles
of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the
transactions contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers,
shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City
of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of
New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated
hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that
it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient
venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any
such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery)
to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any
other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant,
the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&rsquo; fees
and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">f)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Restrictions</U>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered,
and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">g)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder
shall operate as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other
provision of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in
any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses
including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting
any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">h)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Notices</U>. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without
limitation, any Notice of Exercise, shall be in writing and delivered personally, or e-mail, or sent by a nationally recognized overnight
courier service, addressed to the Company, at 11555 Sorrento Valley Road, Suite 203, San Diego, CA 92121, Attention: James Frakes, email
address: accountspayable@aethlonmedical.com, or such other facsimile number, email address or address as the Company may specify for such
purposes by notice to the Holders. Any and all notices or other communications or deliveries to be provided by the Company hereunder shall
be in writing and delivered personally, by facsimile or e-mail, or sent by a nationally recognized overnight courier service addressed
to each Holder at the facsimile number, e-mail address or address of such Holder appearing on the books of the Company. Any notice or
other communication or deliveries hereunder shall be deemed given and effective on the earliest of (i) the time of transmission, if such
notice or communication is delivered via facsimile at the facsimile number or via e-mail at the e-mail address set forth in this Section
prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the date of transmission, if such notice or communication
is delivered via facsimile at the facsimile number or via e-mail at the e-mail address set forth in this Section on a day that is not
a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing,
if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required
to be given. To the extent that the Company, in consultation with its legal counsel, determines that any notice provided in this Warrant
constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall comply
with (i) its disclosure obligations under Regulation FD and (ii) the applicable instructions to Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">i)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the
Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">j)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages,
will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate
compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to
assert the defense in any action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">k)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby
shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted
assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and
shall be enforceable by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">l)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Amendment</U>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company
and the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">m)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT><U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and
valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision
shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining
provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">n)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Headings</U>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be
deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I></I></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I><BR STYLE="clear: both">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>AETHLON MEDICAL, Inc.</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By:__________________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Name:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Title:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">To:</FONT>AETHLON
MEDICAL, INC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(1)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant
(only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes,
if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>Payment shall take the form of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">[ ] in lawful money
of the United States; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">[ ] if permitted the
cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise
this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in
subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(3)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares shall be delivered to the following
DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Investing Entity: ________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of Investing
Entity</I>: _________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: ___________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: ____________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: ________________________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">ASSIGNMENT FORM</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><I>(To assign the foregoing
Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">FOR VALUE RECEIVED, the foregoing
Warrant and all rights evidenced thereby are hereby assigned to</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name:</P></TD>
    <TD STYLE="width: 50%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________________________________</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">(Please Print)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">Address:</TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><U></U>______________________________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Phone Number:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Email Address:</P></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(Please Print)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________________________________</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">Dated: _______________ __, ______</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">Holder&rsquo;s Signature:<U></U>_____________________________________</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">Holder&rsquo;s Address:<U></U>______________________________________</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 14; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
<P STYLE="margin: 0"><B></B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>aemd_ex1001.htm
<DESCRIPTION>FORM OF INDUCEMENT LETTER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>Exhibit 10.1</B></P>

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>AETHLON
MEDICAL, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">11555 Sorrento Valley Road, Suite 203</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">San Diego, CA 92121</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">March 16, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the Holder of May 2024 Class A Warrants and
Class B Warrants</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Re: <U>Inducement Offer to Exercise Existing Class
A Warrants and Class B Warrants</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dear Holder:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Aethlon
Medical, Inc.</FONT> (the &ldquo;<U>Company</U>&rdquo;) is pleased to offer to you the opportunity to exercise all the Class A and Class
B warrants to purchase shares of the Company&rsquo;s common stock, par value $0.001 per share (the &ldquo;<U>Common Stock</U>&rdquo;),
currently held by you (the &ldquo;<U>Holder</U>,&rdquo; &ldquo;<U>you</U>&rdquo; or similar terminology) and issued to you on May 17,
2024 (collectively, the &ldquo;<U>May 2024 Warrants</U>&rdquo;). The number of shares (the &ldquo;<U>Warrant Shares</U>&rdquo;) underlying
the May 2024 Warrants that the Holder agrees to exercise (the &ldquo;<U>Existing Warrants</U>&rdquo;) on terms set forth herein and as
set forth on the signature page hereto are registered pursuant to registration statement on Form S-1 (File No. 333-278188) (the &ldquo;<U>Registration
Statement</U>&rdquo;). The Registration Statement is currently effective and, upon exercise of the Existing Warrants pursuant to this
letter agreement, will be effective for the resale or issuance, as the case may be, of the Warrant Shares if sold pursuant thereto. Capitalized
terms not otherwise defined herein shall have the meanings set forth in the New Warrants (as defined hereinafter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In consideration for exercising
the Existing Warrants held by you and set forth on the Holder&rsquo;s signature page hereto (the &ldquo;<U>Warrant Exercise</U>&rdquo;)
for the Existing Warrants, the Company hereby offers to issue to you or your designee (i) a new unregistered Common Stock Purchase Warrant
(&ldquo;<U>New Warrant</U>&rdquo;) pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (&ldquo;<U>Securities Act</U>&rdquo;),
to purchase up to a number of shares equal to 200% of the number of Warrant Shares issued pursuant to the exercise of Existing Warrants
pursuant to this Agreement (the &ldquo;<U>New Warrant Shares</U>&rdquo;), which New Warrant shall have an exercise price per share equal
to $0.3736, subject to adjustment as provided in the New Warrant, will be exercisable at any time on or after six (6) months from the
date of issuance and have a term of exercise of five and one-half (5.5) years from the date of issuance and (ii) a reduction of the exercise
price of the Existing Warrants to $0.3736 per share, but only with respect to a cash exercise under&nbsp;the Existing Warrants (as reduced
from the current respective exercise price per share as set forth in the Existing Warrants).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The New Warrant certificates
will be delivered within two (2) Trading Days following the Warrant Exercise, and such New Warrants, together with any underlying shares
of Common Stock issued upon exercise of the New Warrants, shall, unless and until registered, contain customary restrictive legends and
other language typical for an unregistered warrant and unregistered shares. Notwithstanding anything herein to the contrary, in the event
that any Warrant Exercise would otherwise cause the Holder to exceed the beneficial ownership limitations (&ldquo;<U>Beneficial Ownership
Limitation</U>&rdquo;) set forth in Section 2(e) of the Existing Warrants (or, if applicable and at the Holder&rsquo;s election, 9.99%),
the Company shall only issue such number of Warrant Shares to the Holder that would not cause the Holder to exceed the maximum number
of Warrant Shares permitted thereunder, as directed by the Holder, with the balance to be held in abeyance until notice from the Holder
that the balance (or portion thereof) may be issued in compliance with such limitations, which abeyance shall be evidenced through the
Existing Warrants which shall be deemed prepaid thereafter (including the payment in full of the exercise price), and exercised pursuant
to a Notice of Exercise in the Existing Warrants (provided no additional exercise price shall be due and payable). The parties hereby
agree that the Beneficial Ownership Limitation for purposes of the Existing Warrants is as set forth on the Holder&rsquo;s signature page
hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Expressly subject to the paragraph
immediately following this paragraph below, the Holder may accept this offer by signing this letter below, with such acceptance constituting
the Holder&rsquo;s exercise in full of the Existing Warrants for an aggregate exercise price set forth on the Holder&rsquo;s signature
page hereto (the &ldquo;<U>Warrants Exercise Price</U>&rdquo;) on or before 8:00 p.m., Eastern Time, on March 16, 2025 (the &ldquo;<U>Execution
Time</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company agrees to the
representations, warranties and covenants set forth on <B>Annex A</B> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Holder represents and
warrants that, as of the date hereof it is, and on each date on which it exercises any New Warrants it will be, an &ldquo;accredited investor&rdquo;
as defined in Rule 501 of Regulation D promulgated under the Securities Act, and agrees that the New Warrants will contain restrictive
legends when issued, and neither the New Warrants nor the shares of Common Stock issuable upon exercise of the New Warrants will be registered
under the Securities Act, except as provided in <B>Annex A</B> attached hereto. Also, Holder represents and warrants that it is acquiring
the New Warrants as principal for its own account and has no direct or indirect arrangement or understandings with any other persons to
distribute or regarding the distribution of the New Warrants or the New Warrant Shares (this representation is not limiting Holder&rsquo;s
right to sell the New Warrant Shares pursuant to an effective registration statement under the Securities Act or otherwise in compliance
with applicable federal and state securities laws).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Holder understands that
the New Warrants and the New Warrant Shares are not, and may never be, registered under the Securities Act, or the securities laws of
any state and, accordingly, each certificate, if any, representing such securities shall bear a legend substantially similar to the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.75in; text-align: justify">&ldquo;<B>THIS SECURITY HAS NOT BEEN REGISTERED
WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION
UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT
TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT
TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.</B>&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the Holder&rsquo;s exercise
of the New Warrants, certificates evidencing the New Warrant Shares shall not contain any legend (including the legend set forth above),
(i) while a registration statement covering the resale of such New Warrant Shares is effective under the Securities Act, (ii) following
any sale of such New Warrant Shares pursuant to Rule 144 under the Securities Act, (iii) if such New Warrant Shares are eligible for sale
under Rule 144 (assuming cashless exercise of the New Warrants), without the requirement for the Company to be in compliance with the
current public information requirement under Rule 144 as to such New Warrant Shares and without volume or manner-of-sale restrictions,
(iv) if such New Warrant Shares may be sold under Rule 144 (assuming cashless exercise of the New Warrants) and the Company is then in
compliance with the current public information requirement under Rule 144 as to such New Warrant Shares, or (v) if such legend is not
required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff
of the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;)) and the earliest of clauses (i) through (v), (the &ldquo;<U>Delegend
Date</U>&rdquo;). The Company shall cause its counsel to issue a legal opinion to the Transfer Agent promptly after the Delegend Date
if required by the Company and/or the Transfer Agent to effect the removal of the legend hereunder, or at the request of the Holder, which
opinion shall be in form and substance reasonably acceptable to the Holder. From and after the Delegend Date, such New Warrant Shares
shall be issued free of all legends, provided that, upon request of the Company (which request shall also include a form of customary
representation letter), the Holder has delivered in advance to the Company a customary representation letter that is reasonably satisfactory
to the Company and its counsel. The Company agrees that following the Delegend Date or at such time as such legend is no longer required
under this Section, it will, no later than two (2) Trading Days following the delivery by the Holder to the Company or the Transfer Agent
of a certificate representing the New Warrant Shares issued with a restrictive legend (such second (2nd) Trading Day, the &ldquo;<U>Legend
Removal Date</U>&rdquo;), deliver or cause to be delivered to the Holder a certificate representing such shares that is free from all
restrictive and other legends or, at the request of the Holder, shall credit the account of the Holder&rsquo;s prime broker with the Depository
Trust Company System as directed by the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the Holder&rsquo;s
other available remedies, the Company shall pay to a Holder, in cash, (i) as partial liquidated damages and not as a penalty, for each
$1,000 of New Warrant Shares (based on the VWAP of the Common Stock on the date such New Warrant Shares are submitted to the Transfer
Agent) delivered for removal of the restrictive legend, $10 per Trading Day (increasing to $20 per Trading Day five (5) Trading Days after
such damages have begun to accrue) for each Trading Day after the Legend Removal Date until such certificate is delivered without a legend
and (ii) if the Company fails to (a) issue and deliver (or cause to be delivered) to the Holder by the Legend Removal Date a certificate
representing the New Warrant Shares free from all restrictive and other legends and (b) if after the Legend Removal Date the Holder purchases
(in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the Holder of all or any portion
of the number of shares of Common Stock, or a sale of a number of shares of Common Stock equal to all or any portion of the number of
shares of Common Stock that the Holder anticipated receiving from the Company without any restrictive legend, then, an amount equal to
the excess of the Holder&rsquo;s total purchase price (including brokerage commissions and other out-of-pocket expenses, if any) for the
shares of Common Stock so purchased (including brokerage commissions and other out-of-pocket expenses, if any) (the &ldquo;<U>Buy-In Price</U>&rdquo;)
over the product of (A) such number of New Warrant Shares that the Company was required to deliver to the Holder by the Legend Removal
Date and for which the Holder was required to purchase shares to timely satisfy delivery requirements, multiplied by (B) the weighted
average price at which the Holder sold that number of shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If this offer is accepted
and the transaction documents are executed by the Closing, then on or before 8:00 a.m., Eastern Time, on the Trading Day following the
date hereof, the Company shall issue a press release and/or file a Current Report on Form 8-K with the Commission disclosing all material
terms of the transactions contemplated hereunder, including this letter agreement as an exhibit thereto with the Commission within the
time required by the Exchange Act. From and after the issuance of such press release or filing of such of such Current Report on Form
8-K, as applicable, the Company represents to you that it shall have publicly disclosed all material, non-public information delivered
to you by the Company, or any of its respective officers, directors, employees or agents in connection with the transactions contemplated
hereunder. In addition, effective upon the issuance of such press release and/or filing of such Current Report on Form 8-K, the Company
acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written or oral, between
the Company, any of its Subsidiaries or any of their respective officers, directors, agents, employees or Affiliates on the one hand,
and you and your Affiliates on the other hand, shall terminate. The Company represents, warrants and covenants that, upon acceptance of
this offer, and upon issuance of the Warrant Shares, the Warrant Shares shall be issued free of any legends or restrictions on resale
by Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No later than the second (2nd)
Trading Day following the date hereof, the closing (&ldquo;<U>Closing</U>&rdquo;) shall occur at such location as the parties shall mutually
agree. Unless otherwise directed by Maxim Group LLC (the &ldquo;<U>Placement Agent</U>&rdquo;), settlement of the Warrant Shares shall
occur via &ldquo;Delivery Versus Payment&rdquo; (i.e., on the Closing Date, the Company shall issue the Warrant Shares registered in the
Holder&rsquo;s name and address provided to the Company in writing and released by the Transfer Agent directly to the account(s) at the
Placement Agent identified by the Holder; upon receipt of such Warrant Shares, the Placement Agent shall promptly electronically deliver
such Warrant Shares to the Holder, and payment therefor shall concurrently be made to the Company by the Placement Agent (or its clearing
firm) by wire transfer to the Company). The date of the Closing of the exercise of the Existing Warrants shall be referred to as the &ldquo;<U>Closing
Date</U>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature Pages to Follow</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>AETHLON MEDICAL, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By:<B>_____________________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name<B>:&#9;</B>James Frakes</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Title:&#9;Chief Executive Officer and Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Holder Signature Page Follows</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page to AEMD Inducement Letter]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Accepted and Agreed to</I>:_________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Holder: <B><U></U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of Holder</I>:
<U>_________________________________________________</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: <U>_________________________________________________</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: <U>_________________________________________________</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Number of Existing Class A Warrants:_________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Number of Existing Class B Warrants:_________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Aggregate Warrant Exercise Price at the Reduced
Exercise Price being exercised contemporaneously with signing this letter agreement: _________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Existing Warrants Beneficial Ownership Blocker:
4.99% or 9.99%</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">New Warrants: _________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">New Warrants Beneficial Ownership Blocker: 4.99%
or 9.99%</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">DTC Instructions: <U>_________________________________________________</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page to AEMD Inducement Letter]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Annex A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Representations, Warranties and Covenants of
the Company</U>. The Company hereby makes the following representations and warranties to the Holder:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">a) <U>SEC Reports</U>. The
Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company under the Exchange
Act, including pursuant to Section 13(a) or 15(d) thereof, for the two years preceding the date hereof (or such shorter period as the
Company was required by law or regulation to file such material) (the foregoing materials, including the exhibits thereto and documents
incorporated by reference therein &ldquo;<U>SEC Reports</U>&rdquo;). As of their respective dates, the SEC Reports complied in all material
respects with the requirements of the Exchange Act and none of the SEC Reports, when filed, contained any untrue statement of a material
fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light
of the circumstances under which they were made, not misleading except as otherwise noted in a subsequent SEC Report. The Company has
never been an issuer subject to Rule 144(i) under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">b) <U>Authorization; Enforcement</U>.
The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this letter
agreement and otherwise to carry out its obligations hereunder. The execution and delivery of this letter agreement by the Company and
the consummation by the Company of the transactions contemplated hereby have been duly authorized by all necessary action on the part
of the Company and no further action is required by the Company, its board of directors or its stockholders in connection herewith other
than the Stockholder Approval, if applicable. This letter agreement has been duly executed by the Company and, when delivered in accordance
with the terms hereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with
its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and
other laws of general application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the
availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution
provisions may be limited by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">c) <U>No Conflicts</U>. The
execution, delivery and performance of this letter agreement by the Company and the consummation by the Company of the transactions contemplated
hereby do not and will not: (i) conflict with or violate any provision of the Company&rsquo;s certificate or articles of incorporation,
bylaws or other organizational or charter documents; or (ii) conflict with, or constitute a default (or an event that with notice or lapse
of time or both would become a default) under, result in the creation of any liens, claims, security interests, other encumbrances or
defects upon any of the properties or assets of the Company in connection with, or give to others any rights of termination, amendment,
acceleration or cancellation (with or without notice, lapse of time or both) of, any material agreement, credit facility, debt or other
material instrument (evidencing Company debt or otherwise) or other material understanding to which such Company is a party or by which
any property or asset of the Company is bound or affected; or (iii) conflict with or result in a violation of any law, rule, regulation,
order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company is subject (including
federal and state securities laws and regulations), or by which any property or asset of the Company is bound or affected, except, in
the case of each of clauses (ii) and (iii), such as could not have or reasonably be expected to result in a material adverse effect upon
the business, prospects, properties, operations, condition (financial or otherwise) or results of operations of the Company, taken as
a whole, or in its ability to perform its obligations under this letter agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">d) <U>Registration Obligations</U>.
The Company shall prepare and file with the Commission a registration statement on Form S-1 providing for the resale of the New Warrant
Shares by the holders of the New Warrants (the &ldquo;<U>Resale Registration Statement</U>&rdquo;) under the Securities Act on or before
the 90<FONT STYLE="font-size: 10pt"><SUP>th</SUP></FONT> calendar day following the date hereof (the &ldquo;<U>Filing Date</U>&rdquo;).
The Company shall use best efforts to cause the Resale Registration Statement to become effective within 120 calendar days following the
date hereof (or, in the event of a &ldquo;full review&rdquo; by the Commission, the 150th calendar day following the date hereof) (the
&ldquo;<U>Effectiveness Date</U>&rdquo;) and to keep the Resale Registration Statement effective at all times until no holder of the New
Warrants owns any New Warrants or New Warrant Shares. In the event that the Resale Registration Statement is not filed by the Filing Date,
then, in addition to any other rights the holders of New Warrants may have hereunder or under applicable law, on the Filing Date (each
such date being referred to herein as an &ldquo;<U>Event Date</U>&rdquo;) and on each monthly anniversary of such Event Date until the
Resale Registration Statement is filed, the Company shall pay to each holder of New Warrants an amount in cash, as partial liquidated
damages and not as a penalty, equal to the product of 1.0% multiplied by the aggregate exercise price of the New Warrants held by each
holder of the New Warrants. If the Company fails to pay any partial liquidated damages pursuant to this Section in full within seven days
after the date payable, the Company will pay interest thereon at a rate of 18% per annum (or such lesser maximum amount that is permitted
to be paid by applicable law) to the holders of the New Warrants, accruing daily from the date such partial liquidated damages are due
until such amounts, plus all such interest thereon, are paid in full. The partial liquidated damages pursuant to the terms hereof shall
apply on a daily pro rata basis for any portion of a month prior to the Resale Registration Statement being filed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">e) <U>Trading Market</U>.
The transactions contemplated under this letter agreement comply with all the rules and regulations of The Nasdaq Capital Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">f) <U>Filings, Consents and
Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing
or registration with, any court or other federal, state, local or other governmental authority or other Person in connection with the
execution, delivery and performance by the Company of this letter agreement, other than: (i) the filings required pursuant to this letter
agreement; (ii) application(s) or notice to each applicable Trading Market for the listing of the New Warrants and New Warrant Shares
for trading thereon in the time and manner required thereby, and (iii) the filing of form D with the Commission and such filings as are
required to be made under applicable state securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">g) <U>Listing of Common Stock</U>.
The Company agrees, if the Company applies to have the Common Stock traded on any other Trading Market, it will then include in such application
all of the New Warrant Shares, and will take such other action as is necessary to cause all of the New Warrant Shares to be listed or
quoted on such other Trading Market as promptly as possible. The Company will then take all action reasonably necessary to continue the
listing and trading of its Common Stock on a Trading Market and will comply in all respects with the Company&rsquo;s reporting, filing
and other obligations under the bylaws or rules of the Trading Market. The Company agrees to maintain the eligibility of the Common Stock
for electronic transfer through the Depository Trust Company or another established clearing corporation, including, without limitation,
by timely payment of fees to the Depository Trust Company or such other established clearing corporation in connection with such electronic
transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">h) <U>Subsequent Equity Sales</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i) From the date hereof until
sixty (60) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce
the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or
any amendment or supplement thereto, in each case other than as contemplated by this Agreement. Notwithstanding the foregoing, this Section
(h)(i) shall not apply in respect of an Exempt Issuance. &ldquo;<U>Exempt Issuance</U>&rdquo; means the issuance of (a) shares of Common
Stock or options or other equity awards to employees, officers, consultants, members of its scientific advisory board or directors of
the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board
of Directors or a majority of the members of a committee of non-employee directors established for such purpose for services rendered
to the Company, (b) securities upon the exercise or exchange of or conversion of any securities of the Company issued hereunder and/or
other securities exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date hereof,
provided that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease
the exercise price, exchange price or conversion price of such securities (other than in connection with stock splits or combinations)
or to extend the term of such securities, (c) securities issued pursuant to acquisitions or strategic transactions approved by a majority
of the non-employee members of the Board of Directors, provided that such securities are issued as &ldquo;restricted securities&rdquo;
(as defined in Rule 144) and carry no registration rights that require the filing of any registration statement in connection therewith
during the prohibition period in Section (h)(i) herein and provided that any such issuance shall only be to a Person (or to the equityholders
of a Person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with
the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not
include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary
business is investing in securities, (d) any securities pursuant to transactions that qualify as &ldquo;exempt issuances&rdquo; that are
as defined and permitted pursuant to any currently outstanding agreements of the Company, and (e) any securities issued in connection
with any Regulation A offering. &ldquo;<U>Person</U>&rdquo; means an individual or corporation, partnership, trust, incorporated or unincorporated
association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other
entity of any kind, for purposes of this Section (h)(i).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii) From the date hereof until
three (3) months following the Closing Date, the Company shall be prohibited from effecting or entering into an agreement to effect any
issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents (or a combination of units thereof) involving
a Variable Rate Transaction. &ldquo;<U>Variable Rate Transaction</U>&rdquo; means a transaction in which the Company (i) issues or sells
any debt or equity securities that are convertible into, exchangeable or exercisable for, or include the right to receive additional shares
of Common Stock either (A) at a conversion price, exercise price or exchange rate or other price that is based upon and/or varies with
the trading prices of or quotations for the shares of Common Stock at any time after the initial issuance of such debt or equity securities,
or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of
such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly related to the business of
the Company or the market for the Common Stock or (ii) enters into, or effects a transaction under, any agreement, including, but not
limited to, an equity line of credit, whereby the Company may issue securities at a future determined price; <I>provided</I>, <I>however</I>,
that, after three (3) months following the Closing Date, the issuance of shares of Common Stock in an &ldquo;at-the-market&rdquo; facility,
or a Regulation A offering shall not be deemed a Variable Rate Transaction. Any Purchaser shall be entitled to obtain injunctive relief
against the Company to preclude any such issuance, which remedy shall be in addition to any right to collect damages. Notwithstanding
the foregoing, this Section shall not apply in respect of an Exempt Issuance, except that no Variable Rate Transaction shall be an Exempt
Issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iii) From the date hereof until
seventy-five (75) days after the Closing Date, the Company shall not announce a reverse split of its Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">i)</TD><TD STYLE="text-align: justify"><U>Form D; Blue Sky Filings</U>. If required, the Company agrees to timely file a Form D with respect
to the New Warrants and New Warrant Shares as required under Regulation D and to provide a copy thereof, promptly upon request of any
Purchaser. The Company shall take such action as the Company shall reasonably determine is necessary in order to obtain an exemption for,
or to qualify the New Warrants and New Warrant Shares for, sale to the Holder at Closing under applicable securities or &ldquo;Blue Sky&rdquo;
laws of the states of the United States, and shall provide evidence of such actions promptly upon request of any Holder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Stockholder Approval</U>. To the extent required under the applicable rules and regulations of the Nasdaq Stock Market LLC (or
any successor entity) in order to approve the Reset of the Exercise Price provision of the New Warrants, the Company shall hold an annual
or special meeting of stockholders on or prior to the date that is one hundred and twenty (120) days following the Issue Date for the
purpose of obtaining Stockholder Approval, with the recommendation of the Company&rsquo;s Board of Directors that such proposals are approved,
and the Company shall solicit proxies from its stockholders in connection therewith in the same manner as all other management proposals
in such proxy statement and all management-appointed proxyholders shall vote their proxies in favor of such proposals. If Stockholder
Approval is not obtained at the first such meeting held pursuant to this paragraph, the Company shall include the such proposal in the
following two (2) annual meetings of stockholders thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Form
of new warrant</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(See attached)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I></I></P>

<!-- Field: Page; Sequence: 9; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<P STYLE="margin: 0"><B></B></P>

<P STYLE="margin: 0"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>aemd-20250216.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +Kopo7xRiXgen8uEbXpMOaCM2aPty5526YkxvmRwfakavygq5Ll2RCSt8rWGAVQJ -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:AEMD="http://aethlonmedical.com/20250216" elementFormDefault="qualified" targetNamespace="http://aethlonmedical.com/20250216">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://aethlonmedical.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="aemd-20250216_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="aemd-20250216_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>aemd-20250216_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>aemd-20250216_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.25b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://aethlonmedical.com/role/Cover" xlink:href="aemd-20250216.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Mar. 16, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 16,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Aethlon
Medical, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000882291<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-3632859<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11555
    Sorrento Valley Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite
    203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">619<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">941-0360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AEMD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( !% <5I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( !% <5ILK+,%[P   "L"   1
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M@2";_-;;I/;=X Q\U*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F
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M[75Y&',&[T)Q UQ?*V7?&\4>N_J+9/(O4$L#!!0    ( !% <5J?H!OPL0(
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M3AI_YHOA/UY_ 5!+ 0(4 Q0    ( !% <5I&QTU(E0   ,T    0
M      "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ $4!Q6FRL
MLP7O    *P(  !$              ( !PP   &1O8U!R;W!S+V-O<F4N>&UL
M4$L! A0#%     @ $4!Q6IE<G",0!@  G"<  !,              ( !X0$
M 'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  10'%:2$(XJF@$   N
M$0  &               @($B"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
M4$L! A0#%     @ $4!Q6I^@&_"Q @  X@P   T              ( !P P
M 'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  10'%:EXJ[',     3 @  "P
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52P4&      D "0 ^ @  %!0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="aemd_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>aemd-20250216.xsd</File>
    <File>aemd-20250216_lab.xml</File>
    <File>aemd-20250216_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="aemd_8k.htm">aemd_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "aemd_8k.htm": {
   "nsprefix": "AEMD",
   "nsuri": "http://aethlonmedical.com/20250216",
   "dts": {
    "schema": {
     "local": [
      "aemd-20250216.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "aemd-20250216_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "aemd-20250216_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "aemd_8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://aethlonmedical.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-16",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aemd_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-16",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aemd_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001683168-25-001631-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001683168-25-001631-xbrl.zip
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M:7K3:HF+D>.6RQ7GI=OIQS@K =9GE+#7;?#*^?FY$^]FT!QR-A TDZXZ9GN
M)2R4]2XIP!,F%6;>&MY7"\(JN.8DFVM0LA5ZFD!)!O5A R?!*XWXQ-$;&N^>
M9,!(VB.,PP5XB.4@%DTWUL!2J#Q0&S=!MIJ'(+="DZTUPO5M]V:!Q:#&E+,
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M072RS9'9RY4&*9&O;OY"TD@DSVHYW]6.ALQYIUM,MOJ^I@D+@;8QF(2:UM/
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M-#4!D6 U!M!PT.;/E'HA8B9')H'IG,5D]S/9@^UJZ=PR =AL0F&( J+"[@S
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M@YJ&MB((%$!;)@<'(=)*QQ#<":(@)+(C\I< 56(A<?OP8)WMN\2NH.@WK.&
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MO135*T K]8Q8607Z356"\EILOU]>WW0M/\G->I/\:X53(K?\%U!+ P04
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M%ITY4;:B=CQC?!/KB9*IC\Z:A/0XN@W*-M$,S2O;?N)\&' RK<:Y9P+DV<4
M6JD&B^@'JF/%YHY+#=@=2R#?'BK?"FT-8R[/G0<Z9<Y?YXJ[]%)W,#PN>(H
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M:2B0;U*JIG90^ZCDPLS6>SM#L#T%H- 15[8&I>+ 7_[<1U[L?PN2K[ &OYT
M$;M7)-9K-^+8+:0HKN0B(<I#/60/Y8ZZL=(OM&'R=V9&U?;]4^[,T.9MH44/
M]:6@44!)5Z&B<:ZM6SOY@Y?6'3LH;\3$M$H8SIZI;,Q9/."2!._+=\R@?!&S
MT I9*'BOB7A2V=S$JWLE8TK=](G>G&V A A8 30DB/GIBU#@/"Z0:>HV$\GX
M:32SHO5=9O(WF5K_@@\-@N6@H<'<Q D0CG07I']N]*+)]>J!3JARRQ0>Z=)<
MVX:>PC=%@.+0^*"^40B,H2),%YT#7;?V@'M7;?&-^^7>QVJ/_ ]02P,$%
M  @ $4!Q6F7,UCG*'@  _JD   L   !A96UD7SAK+FAT;>T]:7?;MK+?^2OP
M?-M;^U22M7J/[I%E.5&]UE*6YHL/1$(28XIDN%A2?_V;P<)-E+?8JM.DY][6
M(H$98#"8'>#!_V83B]PRSS<=^\UOE5+Y-\)LW3%,>_3FMU:OW>W^]K^F=C .
MH!DTM?TW:^,@</<V-Z?3:6E:*SG>:+.RN[N[.<,V:Z+1WBRW7;5<KFQ^.COM
MZ6,VH473]@-JZRSJ9)GVS7+X^#9J.O L,]44GR@DM<T%T/#6B#LD&V]MBI>I
MID%NTX9H&JBFIN_4JY7MN\8A6D0=9LO:5G#,,$/VZ?#J-&X>Y+>/FVX&'K7]
MH>--: !+B) :Q7*U6-U* "GZ3$\!@M^ED7-[+YR=8JVBX"PL3GJF^'I _8CB
M!LN06^&$%]"C6E<-0[\XHM2-&@^I/^!@Y8ML8\^QF)_;FK])-=>=T Z\>?Y
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MU(A^KNDM.8Y7 7)UCY1'-U<#>71K6FPDH"9@W(4NNN"5,^BMPVU> ;,@*U0
MRV-B(.GJ2?Q08,*+%YG2E]&@+QC(_?Z!9\#>D8:K_4S#K3X-5_N9AGNE&^<8
M)!R6E^&='?VXV.?[5&U=H;VB6"HEP\3T$K5,&$[2%NHYTX6B\5D":Y[1(^D@
M+ 9EY0D$^41< L OJHH_@K)$4VD)Q8B>;2$RL>-/U> GLAUY P%.RQ()K7"
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M6]16CLN\A,$9UA*EG /U&_99DKG\15E :NXL,,U<9V3C%S4WV;5L:SH[R_'
M+-W.5 'M, BF91KHMG%";DI6#!;!+Q_ZIQ7\DNYH6'WU:F4((9/3<85?J$(B
MTD?M5CZSJW$;5:$*1CD=>G-IN9+-#PK2:.XZ3VXT\"K%BX*HMN4VE[3$G%!R
M$M5 9F U_.$&1;Y3$+FH)\R(4[=>\J7"_YYR55]5KXF]D%GCPO&%.\CYYZB5
M&KYP7TD[IX T*B8OBDZ:U'Z\J5)DF6LLGNN^8L.3"AOH'D51CAC!$LTG?#76
M9-GH\U%:NIX*57R.FWN.I2#0@_(F"[:>]72C,5D/5RMQ%K,!/6S6< ? P5\W
M@(-' !S\=0,X^'K/XN>U#?G^MK8ANBDCY7R(<KDIS/R5M@W1FPG'/Y%D'W17
M5=#$A(EF7[;-'%BENE].L0K)/>,1>NP"-_,FBI/1;ZZR1'JF4= JU+Y;-/H;
M&HEI#094Q13+=V'$:F(Z"7B^0?+O*2ROP UG+[G(@M_%5R>Z("155V*HS>F'
MR<1YRS#\LHRPNW0@E;+&<ZY,-9J7M20A61*M@WR7(+_R5#$&?#+']BW%'%\F
MUL"#&?I.T'&BO=)E],EV/;$QHBGG:6A?H'Y<$@$XB\(0-,+H13PQ7F-='"M:
M2!6*:IB+REGA"]%"M9\[ K7OQE (7N>#CG4(?1 P;L)L1%O%'G'YN2##SSI2
M0]TXE3WCT@5#0G?N[V#_UCW<3IX2AC>=JAH68<_EAW4\C![)JB\B:5#&^=K2
ML!E=]$6FF89B9.FXPC0^B(5:NZ>H7& [B^.L1/ZSD.1T@>UE+W7O/YM" IN9
M+QJRR:6FG=Y%YI>K18'Z!3IJS7Y[B_*[,0;S5&PSMWR9WJ'*^V#FR1RSTTR*
M87-12O0JKS*W--0MKW+@BZWG7DM=XX?SXV+.5,*&:*HYN\V'4F=YF1P+^KS:
ME%:_$/OIC;LDGMB6B880?C:B[A ?ZN:/MMP;Y<XA/TGJ]B233AY.[90J@DA+
MT:N(4M)]?F3H^.:2_0K;5QS;;2P:;EC=.#3FH"(7-QR2%XP+$M$M9:0J"7L,
MPV"F%,DDB1GJ%CNH,Q=1/)8+T6V[))B&YIO/Q/9)IBY,D_-H*@Y_3_;:T^]P
MJ1O?9H:%2X5/CG:UWW('>O$&"M3%]>[OWV]%O=#I+V^N1:\3*Z%!KIVK07?(
M(?><4UJE"=%QYYNNDG2K&I^3R'\L@5%WJQORG+V(+2;EV/DXCP1O?7GUPBUZ
M4SA>3UVRM]63+(XH5]\SW\8KD Q5G2_F/&C#A+<A(TUQ! L$92UI(\V^DEXN
M5I9544A:GE7/3ZY12GX,@H07PT'T:<! N/07KI0'XY,$8DWP0MU.I59!TV)L
M>*%!_10@BE9Q6&Y27BHYF9&1X5__?5":8.B0%3OT\NN&&#RI,N/5+!16J*(A
M =$4UP@VL]:Q4%X)"7E,(T<J)8*M) V-0YMA>R38=?9<B),3M'E4S@GDZ8(#
MM%+Y;1W#SW-[O+C-[?$N+E!GCU*5S>^Y3>I&9*W9RW&<Z98R<"3/;1 B>$]%
MFW6,[2>PQF"\LN1FZBA ]J/BJD%E&V>*H88"X'$-$M%)I#J9P(N[G;%IS6KJ
MT>5F39$;&JEZ,#ST9E4^P)<M%,<KOC3N;<4@!>TU;< [8)@U?>7Y=O#!]>.(
M.6I0C BTM.^H.QU6[GHLWZ E- +TR*S4B]:!2:T'D*UJ5SSJ28-[/38A_,0?
MT=P$3%Z3V]UZ?[ONB0D=M@0G-7D1WND YT#'*WGB@CC!*Z]1D?#?EN#\4H3!
MFJVQHZR )^&&GX ^<J ,9@]Y[QU<L(D!Z+O.;4\E&&7 2ZS0HWJBE1H5 P&K
M)4XGIJ".4\L#L?A^>2%;3SZA]96\OK&_OJFW/D_9$$6! ]HCC"\1TE77:+&%
M+_P#*^H#XCW%*>',SPXWLX*0D@)@_Z>I]&0VQ826%$Z*2]-ZN=*9QUE-J+&9
M;O]E]KL5.IQ-AS5+QU)XH^(>QC^)7\TOM.(0J$8<\O((4=%6];Q%U!E/>NTL
M,0+K%$<BQA\1U49N1?PR.YX+LRAWI427)%;SZI+)0*P-OQ$Z7XG1Y#7 C,IY
MCL I>!S+W. /;PE\CC^I<N1U::?4$&2=V2P#XTB-":2C+8;2./G)IVF$ ZL'
MLS@W_&]N;^>&HZ*L$0TJ+F;/C1RYWE?!*7%Z(L\COA7.Y\@$Y<ZE;6H^4 E*
M$"I$J@81V-B98</,FS5\06M8!8GRXP:)\@A(E!\W2)0_VEG\ZGI3]G5FZEB4
MZW74OEB-AFO#\]]E_D:3B3,&PX;$)M<XJ?7$+%D=S[D3//ML*8!D:4Y&02JA
M$;^<IX.GD# %1<4DV1 #YHS/-3J6WY.QYN4P@ O7,T"^&AW=%:=)O3R?;TE.
MYGE)V8L5DS*6($]37TB=<VRRZ"AZK2E1BM%52/@OQPK]&<7E8&7YI8XJ4E!]
MSLF$.).!\J<*"_]A4M J+^V%M%=\:=K)D@RK)-'9F:8D=215?"7_#('Q9D52
M?UA7Q/?L.UFE#OY)I;7"9FN*NJNC[-=QEGB:LI/*ET0WW,]"9SB%9(MIE9IU
MZ:E;_]K/?&):M?2ND!4F&#T8+W4L1#;F)Z^G>]#Z;[GRSN1* L<ZV.)6YHT1
MT]%0WW;I,-1[M19 %)^=[8!9C0BVP"@P8(G *7NJ0\YZ1;25Q).1V>&@88 ;
MITJ!;8H"^8,J+5,L!($D7&V4&.T32C0PL 7/S\>@"$:4L5&+.OD5W+4P4!RS
MA+]LL?.6,U((AN5_@Q)-;?KPR-34 *FKIIBP2R$$G8#*H"6<X;X;4G\E5X5<
M]]*\F8)L MN1[&0XPS<1%7GG7&'A7XP>NK"ZIB@^&;4+QTYV^L&VH!:!;^D@
MT^6"NG&"IXX<7Y7.$N55GLTOKT0D^*U7O!(;4D*C)=_<*U3!K(:GAFIU3)R$
M=VJ#8HO!V$H7IB#T=1:/V2NG/I*HI#\@5;(A7INZC13<MY11[50#UIE!*I_6
M"NS"L9S+]<LRB1ML$M]?9G!Q3R+"D10%2#3KX\MS@I @@:7."&,2:0H'X>>X
M,_0S.LFFZ0I@MXC.X&2T&]=IY@BO"5;H:AN5 (DOJRXQ[QQ+-X,\R:GV4CT&
M@L->JE3E4>(DWZ,]<)D1']6]AAB2$$\FY9RQ%(UR6SD:'ZT6D!IFTA=&<EDU
MO),D#XK25?J\$$4$"2F3,Z*6Y]9]S+S;5]?=OI7<U/<HY]O=+QE W]2BFLI"
M4Z4 +;>72NT5%8W*'<,]RK#N"F7$YR,&Y3J:A)K@KA=$D6R(& /GE>6&B:1L
M!TS%53L*1\H4NF8U*G94BT T G1M#[/Q0D/U_@5GM!C'(]V8@U.E##U#2U!:
MC$KUOAKR(1OSL63=K5:#8(UQI[L)ZL>_*O:D!3<+#KIOA8-9.:JVD49DJ,T%
MU+"0-K322LUSG-H=E=1.!H?XU]!RYF/DEF&_TLFT,WPH@*FP\8RV,REH9\BE
M,!+\BW?($G[]YICJ"W XK+D!Y\]P8>2$9SZ*;FSM[M_FJC MZ$;RA !^G&">
M+B<#P@\KK$@&+=_,<$N#BE\VAQH%W8WM<V@! G=&U9HG$&-<AFW$-C(BD9KK
M)&AN&4/JO)00&I+DURS_:/4TVU3#2?S0ZAE,/0'FY[L?[3?-UL$@HJP&ZN.(
M#6 <XXJKV<#U)K&)&L5\2A1U4F%)G]182J+X.QT 4>5/HB9[RS;%)#72*B-2
MM$UGDK!'(LZUC8' B A,^P0OY"*T)2M"8_&'TMA$4FU#&C"EGZ8*Q1Z^"*PK
M6RC2*QF&6S@YQU)D!I9-5<T+;K,H$H_J67*RBL*.2%0/""[:H(BY_*4\MT^M
M$)RM]/9"ZL7%>:ZNLQ&'CN?#:5P6%NLB4_ORRF0VK[X*@KE:AMK+6'.'D=Y%
MZ17F[MCB9'A5C)TR?0*_F\U+MV\*RW^GUI\V8KF^7'EE@<ER-[G,T.W(VV=4
MU7$T+PKCH.#H=@-UR @JI#L=,[)4.T-5*I>K#JD88[:+B0M:]@YU!<1X2F>
MVEA)T;09]6R4E!&OXDN5^*9["-$[=%PQ[3/C+*!D4SX%T8[R-="D2J]5RGE.
M\,-<69>!_?)M;,.$,6^ W6VO)1.,!BD*(YR4H+#UW[GW"_D4QT(_*8:TY%V&
MJ.UR!05L6C2S9;NNX\C%A>(-SH%[^(4J :(3B60V'GA3]8O:!EF<"-:AD8]Z
M5IT7"28@?RD8B,!S+A"&=&-X9R&HBY;6(*X,Y#<5<M7<BF3<<7\9FXW60ER-
M+-5"]SCC-":I[56--@^5TZ"!+"W-O3>2ZF9Z8[+#5\^E]XB-8&E?9SO_PM:
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M2/%D>5#,3@Z/7,7#6'0]"NTL&UPC/W6A7N<E[!)+SRNB_99Z)G$YRCR$;]<
M<OE;9-*ZN WGV E5NA=$[CQ#D:OVVV-SQM9QQM+UBNFWBCR$CDUS)7_!M+*:
M1XPT!*T2&. RVQPY:. Y_Y)*4-EDH(:V(24'+D*J.:C;49IX^GKXJ1D,L]::
MJWJ2_]OPOS5/^>K0O-KANCIH.G-MG5-3$51V"3WSAOS,1>]A9G_(-WW(N;Q9
MEH'B=C>@N,< Q>UN0''K.UU[9WJ24:*B_"4P:GG%]]8ZRTT_2AEN*CUQ>!Q\
M.+PX'IR?!Q_>#LX&)V\J3=NQ$\THHANYVD:&RPV:'DM.U1O.1)FGNA636R?(
M;RHSB7-,NJ/D>_1+8(W->^RS\N50^UFCKGC1WSL:!/N#HZ/ST_[^X?'/)-;P
M]]/^P8'^7597DV6K+;55.CZA(_?JPO!\@PQ\HH_EQ4'#,LRGOY>"%066*,=5
M/+(<Q,A\-E,Y%JZ%Y_9>]P<7;X].CH-W@X/#_?Y1&!RF(V"9/6/"$77O:5WN
MAMW[D*^^NSC _YS=;2?N;RE[BY?_L_+_[I$(-2/F&9T.NNS6/\T%1C'N<YXE
M>_H='?'7ZY-E<"#TY'OK4@_92%Q!GGV]S1@V,V]FWLS\F.U@5K$YGVULSL>P
M.9]M;,ZO^^29W=][?7QR<;@_"$[>!(._#\[V#\\':U0<'M3BNH,1<?_>\HOL
MI9@?8IYT.]8^.=[?]FR3KYO.37Z$K=W>_84)W.9?)F2 $0(*6TE+2P'I*,QL
MXJHB&G&G[95:=Z1*9R>GHU&E_**R':4-TG"+8@OQQ&FQ(*UKI24*@1<DO86"
MQ;H.JPQID%B,"#2-?"L-0;'0HXW+^3VG&2Q]KRB^QRI2NCIG/5LW9YW*/DEW
M*BS.*#4FIY3R 'R 9:SMI@RS3[V77_T.<*&XE>.,N()_!/^D=CG1#; N8?86
MIL'M^Y3BS%1!K/@IR/+'7.@70JJ) Z8BD'!CCZ368HA10?D:NM1@V%;*#3EU
MGD1^$D@Q'Q9.<[?0!8-6NL[20+J(LDC#:?0IGLZG[8L3<5MI+2N]+:L5/#A3
M=8RA.G>16.W)6^5]ET%\3*997<(]7[N$2[@4+16#I>[4]9+@E.[D=&MU[UI.
M"G:2"NE!9D\!N6(,0"79S0/+1=:=5W)</NR2'D;A?9A9+NHU@)ST09W,)F??
M9'MU.P<?^OM!GS-6@V,2)&MFC\<YQ']H)MP0X\LFQK<EBE:U\/]Q?OCS<?_B
M_=F@VSEY$[P].3H8G/WS08SPQW.L<@ -+_!#+B^87@8#S-D!/>(6'ESY?VO?
MX = .[F360P9D,WM(45_SS@5RI"SVV%ZXN(^@Z;?QAG43-9$K7MAM&^#3!1E
M7BN=OA%"'42ENC\!]6W2Z-N9Y;%\B]_6+"M%2Y]OHJ6/$2U]OHF6?CTGRNQT
MS0-WHW 77@8I9FXG3U[WS]&F>#> Q]Z<G+V[Q9889LGXOM;V&&(9S!;BC,/7
M6Q>99 )K9S.WWNIV3!%&@0$S0ICB)ERX?C9+3,/&L5NC9CLXR+CF<^%^RXWB
M<7O0[75F<]SZZ@]EB;2L -@L^*5_]'X0G WV!X>_# ["EBTPY=8D5=RFAI>Z
MF$&N3%V#0MRZ9?8M )%?W",.>04)M,YY#/Z50*1_@!=>787_3*BTYRJJ'KJ6
MX$DS\5<;84M"+:=YG):]!UET7VI#_IYEOWK_&O,P5]V.1T6M/S++GEYEJ?*C
M&>N<;D!E_NP>5V7#FJ>O\O.7(Q"^E'4\R!E'%\FXYB.!W\/ .9._7^JM^STJ
MI<:-\_7E7030U_FNY@C?6=3>YZNN*QWE05/;-Y-L)ME,LIED,\EFDJ]FDI4\
M]M__%)QP)^J7P5%4E!L'_F,X\+]_4 ?^ Q>\<)G=3F&^2#E"7D;0=WLG![_B
MP]^]O7AW]/K_ U!+ P04    "  10'%:*+1]Z)HK  ":Y@  #P   &%E;61?
M97@Q,# Q+FAT;>U]:6\;5Y;H=P+\#W<\G8 "2K+D)8F7-D MCM4CRWH2G;Q@
M,'@HDI=BQ<4JIA;)G%__SG:WJJ*L=%MVVF* V"99=9=SSSW[\O+-Z.W)JW[O
MY9NCX2'\K?"_EZ/CT<G1JY</^6_X]:'\_'+_W>%OZF+TV\G1WQ_,\JQZKO9V
MEY4:)0M=JE-]K<[S19Q%_$6D+G21S![ B_#JF7EO$1>72?9<[3YX]7+_U=''
M>3).*AAG9^_EPWV8]>S&Y[_/QN7RQ;_ZY&W7_D+9,>'1W1>JTA^K[3A-+N&K
MB<XJ7<!<K]^=CLS(]$!5Q%DYRXO%<U4OE[J8Q*6F-0V/1F].WIWV>V^/#H\/
MAB>1.CX]V.$UXBAWO=2]O:=/GZJ+O"C@BUS]$J>I7L%H\11&J9-*JT>[C^]X
M#1=QI@X3?9E'ZF"HGCW:>[1WQS,:3+B327ZORRJ9K1Z\>AL7D[G:^R$"&#YZ
M>M>S?9D]C7)5S;5ZDZ=37:A\IM[&*]S>$W60QF6IANK7N !DKTH59]-^C[_=
MM]]^&U XU\_5R_>OCK-I/=$+0"KU;C8#>, -.OH(MSLI-?PC@:>S2P9,OQ="
M1K4!\_ZN[OH7!LZAC@M!D.??PH[DRR2;:AQT=^=IDMV>Q@]U-4_S# B\GB:3
M. 4"GTUVA+BK 5ZF[]/I'W7^ A#J(%\LXVR%N/!]05]NJ:14RU3#6%-$K]S@
MV2JOZ2;FRV5>5'665"O\6AOT T).OYMK:7&NW]M7UP83X8UE#50*AE?E/"X
M4G"GZ3U>RO=%B<LHU21?+/),E54^^1"I)1SQ59S66OUM=V=W=T_!?GF CBWA
M>Q?XGK^OJ-^;U,1UTI6:ZW2JQBO:5.-]1B1\,Y)7O1_A>6],E<,:DD62PN*
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M9Q,= 8CI)Z000(!6\&)DI@\1126 4'#HWAH8]#OJ(%XF%5"J_]7 9ODXLQP
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M P)?A7L&F3 C*,+>$;J71E 1"HJK*V!1D<%??:61J9 PC/!J@EI=YS6P6R<
M3>*ZU+[<3 +S1*,: %^.=0:"S22!?>37&;#!>;)4*>@/%;'XTN<J^^[9=^;9
M?N_$/ASPM.#F&:;V:*"WUE.405Y$*.O%RV4*D"42BJ)XU24EZ)3'C-2SG6?/
MOB/&YK%VIO]$B9BI$_:M96!58-$AZ#(@49K\! @7\<=D42]D<,+7QNA+U,-
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M(N+-@&\>?9S,464@#0O>0U!T!$;R+[YQQ0$?Q* 4AJ. ETF*?KB2PG",?PF
M$S7'/-0,IG[O$.A&.T8N=!&R<P]5(52"0"UP<4 D?Z%C=)EDY#)C@6M$(:X
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M(<TDO;7Y Y;ZP59T(>J%7*;6=73>W9W/'=#S%<JEF4G^^^7QJPN;HG=&UB8
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M^GV<^3;.F!\VSIBOX(SY8>.,^7+8?R_N^I1TEG._S\X[QP@Z[%BF<(U>8I%
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M,X2;@8)YO\![U+& :L<W,84_>78FM=! )50(^!GU5FO"N-^S0,Z7HE(%\5<
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M"E -'E$J2BN>=QD7P([CY;P+.WTK1+ B 1X&O5E4NL[5X-&68+*9M6RA+QT
MB8?W+"+L3GP+7ZIR\)<MJ/JMSA7,<H.SY:>-L^4K.%M^VCA;_OIWZXO?V2.N
M /O-E'>V<]V^T3KJY>1BR& ^*<Q\%VW7_^6%WEU'^.ZE#2XT)JI7,99?WKK[
M;@YF?W?>J6$SUV:NS5R;N39S;>;:S+69:S/79JY[,E<PRPTVFF<OU+NE-)D[
MB<MJ8[+Y"B:;9U_49/.E#2A? /']%MMW,-D=]_QSP]F'VG;6-<]T&%H>[K\[
M_ V'??AF]/;DU?\'4$L! A0#%     @ $4!Q6DX5!'8O P  ]0L  !$
M         ( !     &%E;60M,C R-3 R,38N>'-D4$L! A0#%     @ $4!Q
M6B'+R6;^"@  @(8  !4              ( !7@,  &%E;60M,C R-3 R,39?
M;&%B+GAM;%!+ 0(4 Q0    ( !% <5JHGC1'70<  .%7   5
M  "  8\.  !A96UD+3(P,C4P,C$V7W!R92YX;6Q02P$"% ,4    "  10'%:
M9<S6.<H>  #^J0  "P              @ $?%@  865M9%\X:RYH=&U02P$"
M% ,4    "  10'%:\,>3$TU(  #VL $ #P              @ $2-0  865M
M9%]E># T,#$N:'1M4$L! A0#%     @ $4!Q6BBT?>B:*P  FN8   \
M         ( !C'T  &%E;61?97@Q,# Q+FAT;5!+!08     !@ & '@!  !3
%J0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>aemd_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="aemd-20250216.xsd" xlink:type="simple"/>
    <context id="AsOf2025-03-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
        </entity>
        <period>
            <startDate>2025-03-16</startDate>
            <endDate>2025-03-16</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-03-16" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-03-16" id="Fact000004">0000882291</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-03-16" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-03-16" id="Fact000010">2025-03-16</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-03-16" id="Fact000011">Aethlon Medical, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-03-16" id="Fact000012">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-03-16" id="Fact000013">001-37487</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-03-16" id="Fact000014">13-3632859</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-03-16" id="Fact000015">11555     Sorrento Valley Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2025-03-16" id="Fact000016">Suite     203</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-03-16" id="Fact000017">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-03-16" id="Fact000018">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-03-16" id="Fact000019">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-03-16" id="Fact000020">619</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-03-16" id="Fact000021">941-0360</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-03-16" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-03-16" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-03-16" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-03-16" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-03-16" id="Fact000026">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-03-16" id="Fact000027">AEMD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-03-16" id="Fact000028">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-03-16" id="Fact000029">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
